PT - JOURNAL ARTICLE AU - Jean Bousquet AU - Shashidhar Rao AU - Volkan Manga TI - Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis DP - 2014 Sep 01 TA - European Respiratory Journal PG - P3483 VI - 44 IP - Suppl 58 4099 - http://erj.ersjournals.com/content/44/Suppl_58/P3483.short 4100 - http://erj.ersjournals.com/content/44/Suppl_58/P3483.full SO - Eur Respir J2014 Sep 01; 44 AB - IntroductionGlobal evaluation of treatment effectiveness is a validated tool, and has been used to evaluate the clinical response to omalizumab at 16 weeks of therapy, in patients with moderate-severe allergic asthma. The relationship of investigator GETE with response to omalizumab was further explored in recent studies of severe allergic asthma.MethodsData from three omalizumab studies (INNOVATE, EXALT & EXTRA) in severe allergic asthma patients were pooled to explore the association of the investigator GETE score at 16 weeks of therapy with the response to the omalizumab treatment vs placebo. A negative binomial model was used to measure the association of the post treatment exacerbation with investigator GETE adjusted for baseline percentage predicted FEV1, treatment received (omalizumab vs placebo), baseline peripheral blood eosinophil count, baseline total IgE level, history of exacerbation, body mass index, age, smoking status & gender.ResultsIn the negative binomial regression model investigator GETE was an accurate predictor of exacerbations (p<0.001). GETE also discriminated and predicted response to omalizumab versus placebo (p<0.001). Annualised exacerbation rates in the omalizumab GETE responders group (0.29) were significantly lower than placebo GETE responders (0.46, relative rate reduction [RRR] 36%, p<0.001) and omalizumab GETE non-responders (0.67, RRR 57%, p<0.001).ConclusionGETE is an accurate predictor of response to omalizumab and can be used as an effective tool to identify omalizumab responders at 16 weeks of therapy. The tool also discriminates between the treatment and placebo responders.